Biohaven Pharmaceutical Holding Co Ltd (BHVN) VP Kimberly Gentile Sells 5,000 Shares of Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) VP Kimberly Gentile sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $21.99, for a total transaction of $109,950.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Kimberly Gentile also recently made the following trade(s):

  • On Wednesday, November 1st, Kimberly Gentile sold 5,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $29.28, for a total transaction of $146,400.00.

Biohaven Pharmaceutical Holding Co Ltd (BHVN) traded down $0.08 during midday trading on Wednesday, reaching $21.10. 532,300 shares of the company’s stock were exchanged, compared to its average volume of 216,377. Biohaven Pharmaceutical Holding Co Ltd has a 1 year low of $17.00 and a 1 year high of $39.51.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter worth $119,000. Nationwide Fund Advisors acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter worth $214,000. American International Group Inc. acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter worth $251,000. State of Wisconsin Investment Board acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter worth $262,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Biohaven Pharmaceutical in the third quarter worth $302,000. Hedge funds and other institutional investors own 47.76% of the company’s stock.

A number of research firms have issued reports on BHVN. Zacks Investment Research upgraded shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. BidaskClub upgraded shares of Biohaven Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price (up from $30.00) on shares of Biohaven Pharmaceutical in a research note on Wednesday, September 13th. Piper Jaffray Companies reiterated a “buy” rating and issued a $54.00 target price on shares of Biohaven Pharmaceutical in a research note on Tuesday, September 12th. Finally, Morgan Stanley lifted their target price on shares of Biohaven Pharmaceutical from $28.00 to $47.00 and gave the company an “overweight” rating in a research note on Monday, September 25th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Biohaven Pharmaceutical currently has an average rating of “Buy” and a consensus price target of $38.17.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/12/06/biohaven-pharmaceutical-holding-co-ltd-bhvn-vp-kimberly-gentile-sells-5000-shares-of-stock.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply